GB9914255D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB9914255D0
GB9914255D0 GBGB9914255.6A GB9914255A GB9914255D0 GB 9914255 D0 GB9914255 D0 GB 9914255D0 GB 9914255 A GB9914255 A GB 9914255A GB 9914255 D0 GB9914255 D0 GB 9914255D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9914255.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Forschung GmbH
Original Assignee
Lilly Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Forschung GmbH filed Critical Lilly Forschung GmbH
Priority to GBGB9914255.6A priority Critical patent/GB9914255D0/en
Publication of GB9914255D0 publication Critical patent/GB9914255D0/en
Priority to PCT/US2000/011882 priority patent/WO2000078724A2/en
Priority to AU57229/00A priority patent/AU5722900A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
GBGB9914255.6A 1999-06-18 1999-06-18 Pharmaceutical compounds Ceased GB9914255D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9914255.6A GB9914255D0 (en) 1999-06-18 1999-06-18 Pharmaceutical compounds
PCT/US2000/011882 WO2000078724A2 (en) 1999-06-18 2000-06-19 Imidazolinderivatives their preparation and their pharmaceutical use
AU57229/00A AU5722900A (en) 1999-06-18 2000-06-19 Pharmaceutical compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914255.6A GB9914255D0 (en) 1999-06-18 1999-06-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB9914255D0 true GB9914255D0 (en) 1999-08-18

Family

ID=10855607

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9914255.6A Ceased GB9914255D0 (en) 1999-06-18 1999-06-18 Pharmaceutical compounds

Country Status (3)

Country Link
AU (1) AU5722900A (en)
GB (1) GB9914255D0 (en)
WO (1) WO2000078724A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006567A (en) 2002-12-20 2005-08-16 Glaxo Group Ltd BENZO aC¦ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS.
US7319152B2 (en) 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
EA022046B1 (en) 2010-07-14 2015-10-30 Новартис Аг Ip receptor agonist heterocyclic compounds
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
CN105189500A (en) 2013-02-13 2015-12-23 诺华股份有限公司 IP receptor agonist heterocyclic compounds
CN107325028B (en) * 2017-08-16 2019-01-18 连云港恒运药业有限公司 Fulvestrant side chain intermediate synthetic method
CN112763671A (en) * 2019-11-04 2021-05-07 南京盛德生物科技研究院有限公司 High-throughput detection method for influence of compound on pancreatic islet function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057324A1 (en) * 1990-12-18 1992-06-19 Lora Louise Fitch Benzamide and sulfonamide hypoglycemic agents
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
FR2756560A1 (en) * 1996-12-04 1998-06-05 Adir NOVEL IMIDAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1999032482A1 (en) * 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds

Also Published As

Publication number Publication date
WO2000078724A2 (en) 2000-12-28
AU5722900A (en) 2001-01-09
WO2000078724A3 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
GB9817118D0 (en) Pharmaceutical compounds
PL351387A1 (en) Pharmaceutical composition
AU1071301A (en) Pharmaceutical compounds
GB9817623D0 (en) Pharmaceutical compounds
GB9810886D0 (en) Pharmaceutical compounds
PL351686A1 (en) Novel pharmaceutical
HUP0203585A3 (en) Pharmaceutical combinations
IL145632A0 (en) Pharmaceutical compounds
GB0031084D0 (en) Pharmaceutical compounds
EG23937A (en) Novel pharmaceutical
GB9916434D0 (en) Pharmaceutical compounds
GB9914255D0 (en) Pharmaceutical compounds
PL351135A1 (en) Novel pharmaceutical
GB9823847D0 (en) Pharmaceutical compounds
GB9903784D0 (en) Pharmaceutical compounds
GB9823845D0 (en) Pharmaceutical compounds
HRP20010951A2 (en) Pharmaceutical complex
EG23946A (en) Novel pharmaceutical
GB0019272D0 (en) Pharmaceutical compounds
GB2373499B (en) Pharmaceutical compounds
GB0024318D0 (en) Pharmaceutical compounds
GB9817197D0 (en) Pharmaceutical compounds
GB0005366D0 (en) Pharmaceutical compounds
GB9923933D0 (en) Novel pharmaceutical
SI1169298T1 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)